Login to Your Account

Analyst: Time For A Takeover?

Cortex Falls As FDA Rejects CX717 Phase IIb In ADHD

By Trista Morrison

Friday, October 12, 2007
Shares of Cortex Pharmaceuticals Inc. plunged 59 percent after the FDA rejected a proposal for a Phase IIb trial of lead ampakine compound CX717 in attention deficit hyperactivity disorder. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription